Dermatology Experts Explored New Oral Treatment Options
Researchers have focused on oral small molecules to expand treatment choices for patients with atopic dermatitis.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Would you prefer oral medication over injectable treatments for skin conditions?
Clinical experts have evaluated new oral treatments and TYK2 inhibitors as alternatives to injectable biologics for atopic dermatitis. These developments aim to address needle aversion among patients while expanding options for conditions like alopecia areata.
Why it matters
The development of oral small molecules provides a crucial alternative for patients who avoid traditional injectable treatments. This shift seeks to improve adherence and patient comfort in the long-term management of dermatological conditions.
There are currently 13 biologics approved for the treatment of psoriasis. Researchers are now prioritizing oral small molecules to provide alternatives to these existing injectable options.
The players
Leon Kircik
He is a clinical researcher based in Louisville who focuses on dermatology and receives research funding from Enveda Biosciences.
The details
Researchers are testing emerging TYK2 inhibitors and first-in-class agents to address a wider range of skin and hair conditions, including vitiligo. These advancements build on existing topical treatments for atopic dermatitis, such as PDE4 inhibitors and tapinarof.
Timeline
Psoriasis biologic development began two decades ago.
New data regarding TYK2 inhibitors is expected at the EADV congress in October 2026.
The Big Picture
The transition toward oral therapies follows trends presented at the European Academy of Dermatology and Venereology (EADV) congress. This movement reflects a broader shift in dermatological science toward providing non-invasive treatment alternatives.
Patients who experience needle aversion may soon have access to new oral treatment options instead of injectable biologics. These developments could simplify daily treatment routines for those managing chronic skin conditions.
The takeaway
The move toward oral small molecules marks a significant step in reducing the burden of care for patients with chronic dermatological needs. Interested patients should discuss emerging clinical trial options with their healthcare providers.
What happens next
New data regarding TYK2 inhibitors will be presented at the EADV congress in October 2026.
Further reading
Learn more about the latest innovations in Asthma care and research.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you prefer oral medication over injectable treatments for skin conditions?
